There are currently 486 clinical trials in Little Rock, Arkansas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Arkansas for Medical Sciences, Arkansas Children's Hospital, GSK Investigational Site and Arkansas Cancer Research Center at University of Arkansas for Medical Sciences. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Prospective Global Registry for the Study of Chronic Total Occlusion Intervention
Recruiting
Percutaneous coronary intervention (PCI) of chronic total occlusions (CTOs) is increasingly being performed in patients with advanced coronary artery disease, but there is limited information on the techniques utilized and the procedural outcomes. The goal of this multicenter, investigator initiated registry is to collect information on treatment strategies and outcomes of consecutive patients undergoing CTO PCI among various participating centers. The information collected will be used to deter... Read More
Gender:
All
Ages:
All
Trial Updated:
03/08/2022
Locations: Little Rock VA Medical Center, Little Rock, Arkansas
Conditions: Coronary Artery Disease
vDOT for Newly Diagnosed Pediatric Asthma
Recruiting
The goal of this research study is to compare the impact of video directly observed therapy on inhaler technique accuracy with participants receiving video directly observed therapy vs. participants receiving standard asthma care. Participants will be randomized between the two groups. We will follow up and compare the two groups to see if they have improved asthma control as measured by symptom-free days, higher inhaler technique at 3-month follow up, higher checklist scores on a standardized i... Read More
Gender:
All
Ages:
Between 6 years and 11 years
Trial Updated:
12/14/2021
Locations: Arkansas Children's Hospital, Little Rock, Arkansas
Conditions: Asthma in Children
Community Translation of the Expecting Study
Recruiting
The Expecting intervention as delivered in prior studies in a clinical setting is described in a previous approved IRB submission (Protocol 202954). The current project will seek to engage community stakeholders to translate Expecting to a community-delivered intervention and to test its acceptability, feasibility, and fidelity in a proof of principle study with 60 expecting mothers.
Gender:
Female
Ages:
18 years and above
Trial Updated:
07/30/2021
Locations: Arkansas Children's Nutrition Center, Little Rock, Arkansas
Conditions: Pregnancy Related
An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis
Recruiting
The present study D5272C00001 (Legacy # 3151-201-008) seeks to evaluate the efficacy and safety of brazikumab versus placebo in patients with moderately to severely active UC and will include assessments of clinical responses as demonstrated by improvement of symptoms and of colonic mucosal appearance as observed on endoscopy.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
01/19/2021
Locations: Research Site, Little Rock, Arkansas
Conditions: Ulcerative Colitis
Temsirolimus Alone or Paired With Dexamethasone Delivered to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization
Recruiting
This is a prospective, multi-center, pilot feasibility study to document the effects of adventitial delivery of temsirolimus or temsirolimus with dexamethasone sodium phosphate injection, USP, after revascularization of femoropopliteal lesions in symptomatic patients with moderate to severe claudication (Rutherford 2-3) or critical limb ischemia (CLI) with rest pain (Rutherford 4). Subjects will be followed for up to 60 months post index procedure.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
08/31/2020
Locations: Arkansas Heart Hospital, Little Rock, Arkansas
Conditions: Peripheral Arterial Disease
Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Patients With Schizophrenia
Recruiting
To evaluate the efficacy and safety of cariprazine at a target dose of 4.5 mg/d compared with placebo in prevention of relapse in patients with schizophrenia To evaluate the efficacy and safety of cariprazine at a target dose of 3.0 mg/d compared with placebo in prevention of relapse in patients with schizophrenia who were initially stabilized on a target dose of 4.5 mg/d
Gender:
All
Ages:
Between 18 years and 64 years
Trial Updated:
08/17/2020
Locations: Woodland International Research Group, Little Rock, Arkansas
Conditions: Schizophrenia